In the present study, APG-1252, as a dual inhibitor of BCL-2 and BCL-XL, was employed to enhance gemcitabine’s antitumor activity based on the consideration that overexpression of anti-apoptotic proteins like BCL-2, BCL-XL, and MCL-1, which play a vital role in the process of tumor survival and chemoresistance [37, 38]. The gene discussed is BCL2L1; the disease is neoplasm.